Cargando…

Intestinal stenosis in Crohn’s disease shows a generalized upregulation of genes involved in collagen metabolism and recognition that could serve as novel anti-fibrotic drug targets

BACKGROUND AND AIMS: Crohn’s disease (CD) can be complicated by intestinal fibrosis. Pharmacological therapies against intestinal fibrosis are not available. The aim of this study was to determine whether pathways involved in collagen metabolism are upregulated in intestinal fibrosis, and to discuss...

Descripción completa

Detalles Bibliográficos
Autores principales: van Haaften, Wouter Tobias, Blokzijl, Tjasso, Hofker, Hendrik Sijbrand, Olinga, Peter, Dijkstra, Gerard, Bank, Ruud A., Boersema, Miriam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457685/
https://www.ncbi.nlm.nih.gov/pubmed/32922514
http://dx.doi.org/10.1177/1756284820952578
_version_ 1783576045613481984
author van Haaften, Wouter Tobias
Blokzijl, Tjasso
Hofker, Hendrik Sijbrand
Olinga, Peter
Dijkstra, Gerard
Bank, Ruud A.
Boersema, Miriam
author_facet van Haaften, Wouter Tobias
Blokzijl, Tjasso
Hofker, Hendrik Sijbrand
Olinga, Peter
Dijkstra, Gerard
Bank, Ruud A.
Boersema, Miriam
author_sort van Haaften, Wouter Tobias
collection PubMed
description BACKGROUND AND AIMS: Crohn’s disease (CD) can be complicated by intestinal fibrosis. Pharmacological therapies against intestinal fibrosis are not available. The aim of this study was to determine whether pathways involved in collagen metabolism are upregulated in intestinal fibrosis, and to discuss which drugs might be suitable to inhibit excessive extracellular matrix formation targeting these pathways. METHODS: Human fibrotic and non-fibrotic terminal ileum was obtained from patients with CD undergoing ileocecal resection due to stenosis. Genes involved in collagen metabolism were analyzed using a microfluidic low-density TaqMan array. A literature search was performed to find potential anti-fibrotic drugs that target proteins/enzymes involved in collagen synthesis, its degradation and its recognition. RESULTS: mRNA expression of collagen type I (COL1A1, 0.76 ± 0.28 versus 37.82 ± 49.85, p = 0.02) and III (COL3A1, 2.01 ± 2.61 versus 68.65 ± 84.07, p = 0.02) was increased in fibrotic CD compared with non-fibrotic CD. mRNA expression of proteins involved in both intra- and extracellular post-translational modification of collagens (prolyl- and lysyl hydroxylases, lysyl oxidases, chaperones), collagen-degrading enzymes (MMPs and cathepsin-K), and collagen receptors were upregulated in the fibrosis-affected part. A literature search on the upregulated genes revealed several potential anti-fibrotic drugs. CONCLUSION: Expression of genes involved in collagen metabolism in intestinal fibrosis affected terminal ileum of patients with CD reveals a plethora of drug targets. Inhibition of post-translational modification and altering collagen metabolism might attenuate fibrosis formation in the intestine in CD. Which compound has the highest potential depends on a combination anti-fibrotic efficacy and safety, especially since some of the enzymes play key roles in the physiology of collagen.
format Online
Article
Text
id pubmed-7457685
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-74576852020-09-11 Intestinal stenosis in Crohn’s disease shows a generalized upregulation of genes involved in collagen metabolism and recognition that could serve as novel anti-fibrotic drug targets van Haaften, Wouter Tobias Blokzijl, Tjasso Hofker, Hendrik Sijbrand Olinga, Peter Dijkstra, Gerard Bank, Ruud A. Boersema, Miriam Therap Adv Gastroenterol Original Research BACKGROUND AND AIMS: Crohn’s disease (CD) can be complicated by intestinal fibrosis. Pharmacological therapies against intestinal fibrosis are not available. The aim of this study was to determine whether pathways involved in collagen metabolism are upregulated in intestinal fibrosis, and to discuss which drugs might be suitable to inhibit excessive extracellular matrix formation targeting these pathways. METHODS: Human fibrotic and non-fibrotic terminal ileum was obtained from patients with CD undergoing ileocecal resection due to stenosis. Genes involved in collagen metabolism were analyzed using a microfluidic low-density TaqMan array. A literature search was performed to find potential anti-fibrotic drugs that target proteins/enzymes involved in collagen synthesis, its degradation and its recognition. RESULTS: mRNA expression of collagen type I (COL1A1, 0.76 ± 0.28 versus 37.82 ± 49.85, p = 0.02) and III (COL3A1, 2.01 ± 2.61 versus 68.65 ± 84.07, p = 0.02) was increased in fibrotic CD compared with non-fibrotic CD. mRNA expression of proteins involved in both intra- and extracellular post-translational modification of collagens (prolyl- and lysyl hydroxylases, lysyl oxidases, chaperones), collagen-degrading enzymes (MMPs and cathepsin-K), and collagen receptors were upregulated in the fibrosis-affected part. A literature search on the upregulated genes revealed several potential anti-fibrotic drugs. CONCLUSION: Expression of genes involved in collagen metabolism in intestinal fibrosis affected terminal ileum of patients with CD reveals a plethora of drug targets. Inhibition of post-translational modification and altering collagen metabolism might attenuate fibrosis formation in the intestine in CD. Which compound has the highest potential depends on a combination anti-fibrotic efficacy and safety, especially since some of the enzymes play key roles in the physiology of collagen. SAGE Publications 2020-08-29 /pmc/articles/PMC7457685/ /pubmed/32922514 http://dx.doi.org/10.1177/1756284820952578 Text en © The Author(s), 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research
van Haaften, Wouter Tobias
Blokzijl, Tjasso
Hofker, Hendrik Sijbrand
Olinga, Peter
Dijkstra, Gerard
Bank, Ruud A.
Boersema, Miriam
Intestinal stenosis in Crohn’s disease shows a generalized upregulation of genes involved in collagen metabolism and recognition that could serve as novel anti-fibrotic drug targets
title Intestinal stenosis in Crohn’s disease shows a generalized upregulation of genes involved in collagen metabolism and recognition that could serve as novel anti-fibrotic drug targets
title_full Intestinal stenosis in Crohn’s disease shows a generalized upregulation of genes involved in collagen metabolism and recognition that could serve as novel anti-fibrotic drug targets
title_fullStr Intestinal stenosis in Crohn’s disease shows a generalized upregulation of genes involved in collagen metabolism and recognition that could serve as novel anti-fibrotic drug targets
title_full_unstemmed Intestinal stenosis in Crohn’s disease shows a generalized upregulation of genes involved in collagen metabolism and recognition that could serve as novel anti-fibrotic drug targets
title_short Intestinal stenosis in Crohn’s disease shows a generalized upregulation of genes involved in collagen metabolism and recognition that could serve as novel anti-fibrotic drug targets
title_sort intestinal stenosis in crohn’s disease shows a generalized upregulation of genes involved in collagen metabolism and recognition that could serve as novel anti-fibrotic drug targets
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457685/
https://www.ncbi.nlm.nih.gov/pubmed/32922514
http://dx.doi.org/10.1177/1756284820952578
work_keys_str_mv AT vanhaaftenwoutertobias intestinalstenosisincrohnsdiseaseshowsageneralizedupregulationofgenesinvolvedincollagenmetabolismandrecognitionthatcouldserveasnovelantifibroticdrugtargets
AT blokzijltjasso intestinalstenosisincrohnsdiseaseshowsageneralizedupregulationofgenesinvolvedincollagenmetabolismandrecognitionthatcouldserveasnovelantifibroticdrugtargets
AT hofkerhendriksijbrand intestinalstenosisincrohnsdiseaseshowsageneralizedupregulationofgenesinvolvedincollagenmetabolismandrecognitionthatcouldserveasnovelantifibroticdrugtargets
AT olingapeter intestinalstenosisincrohnsdiseaseshowsageneralizedupregulationofgenesinvolvedincollagenmetabolismandrecognitionthatcouldserveasnovelantifibroticdrugtargets
AT dijkstragerard intestinalstenosisincrohnsdiseaseshowsageneralizedupregulationofgenesinvolvedincollagenmetabolismandrecognitionthatcouldserveasnovelantifibroticdrugtargets
AT bankruuda intestinalstenosisincrohnsdiseaseshowsageneralizedupregulationofgenesinvolvedincollagenmetabolismandrecognitionthatcouldserveasnovelantifibroticdrugtargets
AT boersemamiriam intestinalstenosisincrohnsdiseaseshowsageneralizedupregulationofgenesinvolvedincollagenmetabolismandrecognitionthatcouldserveasnovelantifibroticdrugtargets